Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.

Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

Hello, everyone, and welcome to Allurion Fourth Quarter Earnings Call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question-and-answer session.

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass., March 20, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or ...